13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001940272
Total reported value
$2.2B
$2.2B
262 檔
9.2%
During the Q3 2024 filing period, ADAR1 Capital Management, LLC (CIK: 0001940272) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $2.2B across 262 reported positions.
During Q3 2024, ADAR1 Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
Showing top 200 holdings (of 262 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CYTK | Cytokinetics Inc | Stock-Healthcare | 7.95% | -0.66% | +8.47% | |
| 2 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 7.18% | -0.78% | -38.82% | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 6.00% | +0.19% | +14.10% | |
| 4 | BOXX | Alpha Architect 1-3 Mnth Box | ETF-Other | 5.73% | -0.50% | -7.99% | |
| 5 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 5.68% | -0.25% | -27.10% | |
| 6 | IMVT | Immunovant Inc | Stock-Other | 5.29% | +0.19% | +139.62% | |
| 7 | RPRX | Royalty Pharma plc | Stock-Healthcare | 5.05% | +0.02% | -7.17% | |
| 8 | KROS | Keros Therapeutics Inc | Stock-Other | 4.21% | +0.06% | -18.86% | |
| 9 | ASND | Ascendis Pharma A/S | Stock-Other | 3.92% | -0.34% | EXIT | |
| 10 | ✓ | Zura Bio LTD | Stock-Other | 2.49% | +0.26% | — | |
| 11 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 2.09% | +1.35% | +2320.25% | |
| 12 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 1.77% | — | +282.01% | |
| 13 | YCY-UN | AA Mission Acquisition Corp. II | Stock-Other | 1.65% | — | — | |
| 14 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.44% | +0.12% | +2775.51% | |
| 15 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.43% | -0.02% | EXIT | |
| 16 | ABUS | Arbutus Biopharma CORP | Stock-Other | 1.31% | -0.55% | -36.48% | |
| 17 | SLDB | Solid Biosciences Inc | Stock-Other | 1.30% | — | -19.35% | |
| 18 | ✓ | Merus N V | Stock-Other | 1.25% | — | +470.90% | |
| 19 | RZLT | Rezolute Inc | Stock-Other | 1.24% | — | -23.85% | |
| 20 | ✓ | Stock-Other | 1.22% | +0.02% | — | ||
| 21 | XNCR | Xencor Inc | Stock-Other | 1.12% | +0.10% | — | |
| 22 | ANAB | Anaptysbio Inc | Stock-Other | 1.05% | — | +22.52% | |
| 23 | RGNX | Regenxbio Inc | Stock-Other | 1.00% | -0.02% | EXIT | |
| 24 | ABVX | Abivax Sa-adr | Stock-Other | 0.98% | +1.85% | +1831.90% | |
| 25 | BIIB | Biogen Inc | Stock-Healthcare | 0.93% | +0.06% | — | |
| 26 | OABI | Omniab Inc | Stock-Other | 0.92% | +0.04% | +87.68% | |
| 27 | CGON | Cg Oncology Inc | Stock-Other | 0.88% | -0.35% | +1013.65% | |
| 28 | APLT | Applied Therapeutics Inc | Stock-Other | 0.74% | — | +68.03% | |
| 29 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.73% | -0.35% | +18.14% | |
| 30 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.69% | — | — | |
| 31 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 0.64% | +0.38% | — | |
| 32 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.63% | — | -64.37% | |
| 33 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.63% | — | +527.89% | |
| 34 | ABSI | Absci CORP | Stock-Other | 0.62% | — | -40.79% | |
| 35 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 0.58% | -0.01% | +14900.00% | |
| 36 | 0C3 | Endeavor Group Hold-class A | Stock-Other | 0.57% | — | +1056.92% | |
| 37 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.55% | +0.19% | NEW | |
| 38 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.53% | -0.27% | EXIT | |
| 39 | SVRA | Savara Inc | Stock-Other | 0.51% | -0.07% | +9.28% | |
| 40 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.48% | -0.91% | +167.96% | |
| 41 | GRCE | Grace Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 42 | QTTB | Q32 Bio Inc | Stock-Other | 0.47% | -0.01% | EXIT | |
| 43 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.45% | +0.10% | +2361.28% | |
| 44 | GERN | Geron CORP | Stock-Other | 0.41% | +0.01% | +519.07% | |
| 45 | ✓ | Stock-Other | 0.39% | — | — | ||
| 46 | MCK | Mckesson CORP | Stock-Healthcare | 0.39% | +0.03% | — | |
| 47 | VIR | Vir Biotechnology Inc | Stock-Other | 0.39% | -0.30% | +190.17% | |
| 48 | CLRBUSD | Cellectar Biosciences Inc | Stock-Other | 0.36% | — | +49.86% | |
| 49 | ALKS | Alkermes plc | Stock-Healthcare | 0.34% | -0.10% | EXIT | |
| 50 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.33% | -0.02% | — |
According to official SEC Form 13F filings, ADAR1 Capital Management, LLC reported a total U.S. public equity portfolio value of $2.2B across 262 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CYTK, PTGX, BBIO) accounted for 9.2% of total reported equity market value during Q3 2024.
During Q3 2024, ADAR1 Capital Management, LLC's top holdings by market value included CYTK (8.0%)、PTGX (7.2%)、BBIO (6.0%). The largest single position, CYTK, represented 8.0% of total portfolio value.
In Q3 2024, ADAR1 Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.